Ritivel
Product & Competitive Intelligence
Automates regulatory medical writing with word-level traceability and reproducible outputs.
Company Overview
AI-native platform that uses domain-specific large language models and AI agents to automate the drafting, tracing, and management of regulatory and medical documents (CTDs, CSRs, INDs, BLAs) for pharmaceutical, biotech, and CRO customers, with word-level traceability, 100% reproducibility, and fully local deployment.
Competitive Advantage & Moat
Product Roadmap & Public Announcements
Ritivel has publicly announced core capabilities including AI-driven drafting of CTDs, CSRs, INDs, and BLAs directly in Microsoft Word, word-level traceability for every claim with one-click source verification, 100% reproducible outputs, zero cloud storage, and integrations with SharePoint, Veeva, and Outlook. Their YC W26 profile highlights regulatory search across all documents and automated workflow agents for document gathering and follow-ups. All aimed at replacing months of manual regulatory writing with minutes of AI-assisted drafting.
Signals & Private Analysis
No public GitHub repos, patents, or conference appearances suggest a stealth-mode, proprietary development approach. The absence of job postings indicates the founding team is heads-down building core IP rather than scaling. LinkedIn activity is minimal, and no Product Hunt or Hacker News launches have occurred. Strong indicators point to near-term expansion into additional regulatory document types (e.g., eCTD Module 2 summaries, DSUR, PBRER), deeper Veeva Vault integration, and potential partnerships with CROs for distribution. The local-deployment-first architecture signals a likely move toward validated, GxP-compliant AI environments for enterprise pharma customers.
Product Roadmap Priorities
AI-powered automated drafting of regulatory submission documents (CTDs, CSRs, INDs, BLAs) with word-level source traceability, replacing months of manual medical writing with minutes of AI-generated, audit-ready output.
Instead of a team of writers spending months manually assembling a drug approval document, Ritivel's AI drafts the entire thing in minutes and shows exactly where every fact came from.
It's like having a paralegal who can write an entire FDA filing in the time it takes you to brew coffee—and who highlights exactly which page of evidence backs up every single sentence.
NLP-powered regulatory intelligence search that enables instant extraction and cross-referencing of data points, precedents, and requirements across entire regulatory document repositories.
Instead of manually hunting through thousands of pages of past submissions to find a relevant precedent or data point, Ritivel's AI instantly searches everything and pulls exactly what you need.
It's like replacing a room full of filing cabinets and a magnifying glass with a search engine that actually understands what "bioequivalence" means and where you last mentioned it.
AI agent-driven workflow automation that orchestrates document gathering, stakeholder follow-ups, and submission assembly across distributed teams and enterprise systems.
Instead of a project manager chasing dozens of people via email for missing documents and approvals, Ritivel's AI agents automatically track what's needed, remind the right people, and assemble everything on schedule.
It's like having a hyper-organized wedding planner who never forgets a vendor, never loses an RSVP, and somehow gets your uncle to return his suit rental on time—except the wedding is an FDA submission.
Company Overview
Key Team Members
- Pavan Kalyan Tankala (PK), Co-Founder & CEO
- Nirmit Arora, Co-Founder & CTO
- Gunin Gupta, Co-Founder & CBO
Founder Force Multiplier
Ritivel's founding team combines Pavan Kalyan Tankala's and Nirmit Arora's experience building AI copilots at Microsoft Research with domain-specific LLM training for life sciences, and Gunin Gupta's strategy consulting background at AT Kearney focused on sustainability and energy process industries. All three are IIT Bombay alumni, with PK holding publications at NeurIPS, ACL, and Interspeech, enabling them to deliver deterministic, traceable, and locally deployable AI outputs that meet the stringent reproducibility and auditability standards unique to pharmaceutical regulatory submissions.
Funding History
- 2025 | Pavan Kalyan Tankala, Nirmit Arora, and Gunin Gupta co-found Ritivel.
- 2026 | $500K Seed round from Y Combinator.
- 2026 | Accepted into Y Combinator Winter 2026 batch.
- 2026 | Product in early-stage development; no additional funding rounds disclosed.
Competitors
- AI Regulatory Writing: Glemser Technologies, Akkio (generic AI), various pharma consulting firms.
- Traditional Medical Writing CROs: Parexel, IQVIA, Certara.
- Document Automation: Veeva Vault (incumbent platform), MasterControl, Documentum.
- AI-Native Competitors: Linguamatics (IQVIA), Saama Technologies, Insilico Medicine (adjacent AI-pharma).
- Emerging: Various stealth AI-for-regulatory startups, including Weave, Artos, X Doc.
